| Feature Story: |
Boston Scientific Announces Agreement To Acquire Augmenix, Inc. |
Boston Scientific announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the SpaceOAR® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy. The transaction consists of an upfront cash payment of $500 million, and up to $100 million for reaching sales-based milestones.
Each year, more than 1.1 million men are diagnosed with prostate cancer worldwide and approximately 400,000 men will undergo prostate radiotherapy. One of the most common complications of treatment is...
Click here to read more |
|
|
 An analysis of endoscopic gastro-intestinal procedure volumes by iData Research shows that over 19 million colonoscopies are performed annually, as reported in 2017, a significant contribution to the 75 million endoscopies performed each year in the United States. A major factor driving growth in colonoscopy procedures is the increasing public awareness of colon cancer, through media campaigns initiated by cancer awareness groups and government bodies, as well as an aging population that is recommended to receive regular screenings.
The U.S. screening program, in particular, has been...
read more}
|
|
 Bayer has made a business decision to voluntarily discontinue sales and distribution of the Essure® System for Permanent Birth Control in the United States after December 31, 2018. This decision is based on a decline in U.S. sales of Essure in recent years and the conclusion that the Essure business is no longer sustainable. Essure is the only FDA-approved non-incisional form of permanent birth control.
The benefit-risk profile of Essure has not changed, and we continue to stand behind the product’s safety and efficacy, which are demonstrated by an extensive body of research, undertaken by Bayer and independent medical researchers, involving more than 200,000...
read more}
|
|
 According to a recent press release from Abbott, “the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. This approval makes Abbott’s revolutionary continuous glucose monitor (CGM) the longest lasting self-applied personal glucose sensor available on the market.”
Here’s what our analysts have to say about this new update in the U.S. diabetes market:
After leaving the continuous glucose monitoring (CGM) market in 2011, when it discontinued its FreeStyle Navigator product line, Abbott re-entered the market in 2016 with...
read more}
|
|
 According to the latest results from iData Research’s medical imaging procedures analysis, over 75 million CT scans are performed each year in the United States. This number is forecasted to grow to reach 84 million procedures by 2022, despite the significant concerns about radiation exposure.
The majority of CT scan procedures performed are for diagnostic purposes, particularly for the head, neck and facial regions. In recent years, there has been a surge in popularity for CT scanner usage in cardiac procedures, most notably cardiac CT angiography. These scans require premium systems with higher image resolutions. Higher-resolution systems, as expected, are...
read more}
|
|
 Inspire Medical Systems, Inc. (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced that Aetna Inc., one of the leading health plans in the United States, will provide coverage for the Company’s Inspire therapy, effective immediately. Aetna’s plan provides coverage for approximately 22 million members.
“We are very pleased to receive this positive coverage decision from Aetna. We believe this coverage decision is a major milestone and has the potential to...
read more}
|
|
 Dysis Medical said it raised $25 million (GBP £18 million) in a new round to help support its Dysis colposcope used for cervical cancer screenings.
The Dysis colposcope uses both optical imaging and software to scan the cervix to improve cervical cancer screening procedures, the company said.
Funds in the round will help support expansion into the US, across the U.K. and in “other key territories,” the Edinburgh, Scotland-based company said. Funds may also be used to support strategic R&D.
“We are excited to support the rapid growth of Dysis Medical and the advancement of the Dysis colposcope. We recognize the momentum the company is achieving globally and we are...
read more}
|
|
|
|
|
|
|
|
